Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_67bf280a23817fdc0f1cd4dc93ff0b98 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-197 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-05 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-185 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-197 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-08 |
filingDate |
2020-05-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_566de262aacb6246218a4dea506ca2f0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0bbef9301d13fcd7e08d9870245798b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd5cf4d69b4b80deff9d0584852e74ce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_624658f4040412c0cdf967962b2b9d6a |
publicationDate |
2020-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2020225540-A1 |
titleOfInvention |
Use of cannabidiol in the treatment of tuberous sclerosis complex |
abstract |
The present invention relates to the use of a cannabidiol (CBD) preparation for use in the treatment of seizures associated with tuberous sclerosis complex (TSC). Preferably the CBD used is in the form of a botanically derived purified CBD which comprises greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) of other cannabinoids. The other cannabinoids present are THC at a concentration of less than or equal to 0.1% (w/w); CBD-C1 at a concentration of less than or equal to 0.15% (w/w); CBDV at a concentration of less than or equal to 0.8% (w/w); and CBD-C4 at a concentration of less than or equal to 0.4% (w/w). The botanically derived purified CBD preferably also comprises a mixture of both trans-THC and cis- THC. Alternatively, a synthetically produced CBD is used. In use the CBD is given concomitantly with one or more other anti-epileptic drugs (AED). Alternatively, the CBD may be formulated for administration separately, sequentially or simultaneously with one or more AED or the combination may be provided in a single dosage form. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-2601755-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022123236-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023007152-A1 |
priorityDate |
2019-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |